PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 1, 1979Cancer78 citationsOpen Access

Pulmonary resection for metastatic nonosteogenic sarcoma

View Full Paper
ECEdward T. CreaganTFThomas R. FlemingJEJohn H. Edmonson

Key Result

Pulmonary resection for metastatic nonosteogenic sarcoma yielded a 5-year survival of 29% and median survival of 18 months, with worse prognosis for disease-free intervals <12 months (p<0.01).

Study Design

Type

Observational (n=112)

Multicenter

No

Structured PICO

What is the survival outcome following pulmonary resection for metastatic nonosteogenic sarcoma?

P
Population
112 patients who underwent resection of metastatic pulmonary nodules for nonosteogenic sarcoma at the Mayo Clinic from 1950-1976
I
Intervention
Pulmonary resection (thoracotomy)
O
Outcome
Post-thoracotomy survival (5-year survival and median survival)hard clinical

Pulmonary resection for metastatic nonosteogenic sarcoma yields a 29% 5-year survival, with poorer outcomes in patients with short disease-free intervals or extrathoracic recurrences.

Limitations

  • Whether the recent more common use of thoracotomy in metastatic disease of this type is therapeutically worthwhile cannot be clearly determined from the data available.

Abstract

Analysis was made of 112 patients who underwent resection of metastatic pulmonary noldules for nonosteogenic sarcoma at the Mayo Clinic from 1950--76. The 5-year post-thoracotomy survival was 29% with a median survival of 18 months. There has been no substantial change between 1950 and 1976 in post-thoracotomy survival among all patients who received this operation here. Prognosis was especially grim (p less than 0.01) for patients with pre-thoracotomy disease-free intervals of less than 12 months, and for those experiencing extrathoracic recurrences vs. further pulmonary recurrent tumor (p = .01) following thoracotomy. The following discriminants were not significantly associated with postthoracotomy survival: age, sex, histology, number of lesions fully excised, or site of lung lesions. We conclude that the therapeutic value of thoracotomy in the treatment of metastatic nonosteogenic sarcomas has not changed here during the past quarter of a century. Whether the recent more common use of thoracotomy in metastatic disease of this type is therapeutically worthwhile cannot be clearly determined from the data available.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Creagan et al. (1979) conducted an observational in Metastatic nonosteogenic sarcoma (n=112). Pulmonary resection (thoracotomy) was evaluated on 5-year post-thoracotomy survival. Pulmonary resection for metastatic nonosteogenic sarcoma yielded a 5-year survival of 29% and median survival of 18 months, with worse prognosis for disease-free intervals <12 months (p<0.01).

synapsesocial.com/papers/6a0c7abe106bfae851887317https://doi.org/10.1002/1097-0142(197911)44:5<1908::aid-cncr2820440553>3.0.co;2-2
Ask AI
Helpful
Bookmark
Share
View Full Paper